Camacho R

Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe

Autores: Asboe D, Bansi L, Camacho R, Codoñer FM, De Luca A, Di Giambenedetto S, Dunn D, Fanti I, Ghisetti V, Kaiser R, Prosperi MCF, Sönnerborg A, Torti C, van de Vijver DC, Van Laethem K, Vandamme AM, Zazzi M
Ano de Publicação: 2013
Journal: Journal of Infectious Diseases
Link: http://jid.oxfordjournals.org/content/early/2013/01/11/infdis.jit017.abstract

HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20,323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis.
Ler mais

Study of the regimen-specific HIV-1 genotypic susceptibility score after treatment failure

Autores: Beheydt G, Camacho R, Carvalho AP, Diogo I, Grossman Z, Ram D, Rudich H, Van Laethem K, Vandamme AM, Zazzi M
Ano de Publicação: 2010
Journal: Antiviral Therapy
Link: https://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=3&SID=Z1yZbyGlNxI3xGo9eDj&page=1&doc=1

Ler mais

Expected HIV-1 etravirine resistance after treatment failure with efavirenz and/or nevirapine

Autores: Beheydt G, Camacho R, Carvalho AP, Grossman Z, Levy I, Ram D, Rudich H, Van Laethem K, Vandamme AM, Vercauteren J
Ano de Publicação: 2010
Journal: Antiviral Therapy
Link: https://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=2&SID=Z1yZbyGlNxI3xGo9eDj&page=1&doc=1

Ler mais

Origin and Epidemiological History of HIV-1 CRF14_BG

Autores: Abecasis AB, Barroso H, Bártolo I, Borrego P, Camacho R, Gomes P, McCutchan F, Taveira N
Ano de Publicação: 2011
Journal: PLoS One
Link: https://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=26&SID=P2WA5hwy5j35Sqjoq2z&page=1&doc=1

Background: CRF14_BG isolates, originally found in Spain, are characterized by CXCR4 tropism and rapid disease progression. This study aimed to identify the origin of CRF14_BG and reconstruct its epidemiological history based on new isolates from Portugal.
Ler mais

Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response

Autores: Beheydt G, Camacho R, Clotet B, De Luca A, Geretti AM, Grossman Z, Imbrechts S, Kaiser R, Libin P, Prosperi M, Schmit JC, Sönnerborg A, Torti C, Van Laethem K, Van Wijngaerden E, Vandamme AM, Vercauteren J, Zazzi M
Ano de Publicação: 2013
Journal: PLoS One
Link: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0061436

Clinically evaluating genotypic interpretation systems is essential to provide optimal guidance in designing potent individualized HIV-regimens. This study aimed at investigating the ability of the latest Rega algorithm to predict virological response on a short and longer period.
Ler mais

Patterns of Transmitted HIV drug resistance in Europe vary by risk group

Autores: Abecasis A, Albert J, Åsjö B, Balotta C, Bergin C, Beshkov D, Boucher C, Camacho R, Clotet B, Frentz D, Griskevicius A, Grossman Z, Hamouda O, Horban A, Jørgensen L, Kolupajeva T, Korn K, Kostrikis L, Kücherer C, Linka KL, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Programme AW, Puchhammer-Stöckl E, Schmit JC, Sönnerborg A, Staneková D, Stanojevic M, Struck D, van de Vijver D, Vandamme AM, Vercauteren J
Ano de Publicação: 2014
Journal: PLoS One
Link: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0094495

In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported.
Ler mais